COVAXIN: News
Bharat Biotech includes ICMR as co-owner of COVAXIN patent
Bharat Biotech International (BBIL), a Hyderabad-based biotech company, has added the Indian Council of Medical Research (ICMR) as a co-owner to the patent for their COVID-19 vaccine, COVAXIN.
'Poor methodology': ICMR dissociates itself from Covaxin safety study
The Indian Council of Medical Research has disassociated itself from a Covaxin vaccine study conducted by the Banaras Hindu University (BHU).
After Covishield, new study finds side effects in Covaxin recipients
A recent study published in Springer Nature revealed that over 30% of Covaxin recipients reported "adverse events of special interest" (AESI).
Bharat Biotech completes third-phase of intranasal COVID-19 vaccine trials
The manufacturing body of the made-in-India Covaxin is only steps away from releasing its intranasal vaccine for the virus.
Centre denies asking Bharat Biotech to address WHO's COVAXIN suspension
The Ministry of External Affairs (MEA) on Friday denied reports that it had asked Bharat Biotech to address issues to avoid the cancellation of the World Health Organization's (WHO) emergency approval for its COVAXIN.
DCGI clears COVAXIN, Corbevax for children aged 6-12, 5-12 years
In a significant move, the Drugs Controller General of India (DCGI) on Tuesday cleared two COVID-19 vaccines for use in children aged between five and 12 years.
COVAXIN likely to get approval for children above 2yrs: Report
Bharat Biotech's COVID-19 vaccine, COVAXIN, is likely to get the Drugs Controller General of India's (DCGI) nod for use among children aged two to 12 years.
COVAXIN, Covishield will now be available in hospitals and clinics
The Drugs Controller General of India (DCGI) on Thursday granted approval for regular market sale to India's two most prevalent COVID-19 vaccines—COVAXIN and Covishield.
COVAXIN supply to be increased as teens get COVID-19 vaccines
Pharmaceutical firm Bharat Biotech on Monday said it plans to increase the supply of its COVID-19 vaccine COVAXIN to up to eight crore doses a month, starting February.
COVAXIN found 50% effective against COVID-19 in first real-world study
COVAXIN, India's indigenous coronavirus vaccine, is 50% effective against symptomatic COVID-19, the first real-world study of its effectiveness suggests.
UK to add COVAXIN to approved vaccines from November 22
The government of United Kingdom has said that India's coronavirus vaccine COVAXIN will be added to its list of approved vaccines for international travelers.
COVID-19: India reports 11K new cases, 526 more deaths
India on Sunday reported nearly 11,000 new COVID-19 cases with an active caseload of 1.44 lakh, the lowest in 260 days.
COVAXIN gets WHO approval for emergency use listing
The World Health Organization (WHO) on Wednesday granted Emergency Use Listing (EUL) to COVAXIN.
Australia accepts COVAXIN as 'recognized' vaccine for incoming travelers
Australia on Monday accepted India's indigenous vaccine, COVAXIN, as a "recognized" vaccine for the purpose of travel to the country.
COVAXIN under review; may get WHO recommendation in 24 hours
A technical advisory group of the World Health Organization (WHO) is reviewing data on COVAXIN and may recommend emergency use approval for the vaccine within 24 hours, an official said.
Vaccination for children can wait as trial still underway: Expert
India's top virologist Dr. Gagandeep Kang has said that there should not be any hurry to vaccinate children against COVID-19 as vaccine trials are ongoing and immunogenicity data is still awaited.
Cannot cut corners, thorough evaluation needed for COVAXIN EUL: WHO
The World Health Organization (WHO) Monday clarified the reason behind the delay in COVAXIN's emergency use listing (EUL), stating that it is expecting more information from Bharat Biotech on its COVID-19 vaccine.
WHO expert panel to discuss COVAXIN approval in meet today
COVAXIN, India's indigenous vaccine against the coronavirus, will likely receive the much-awaited approval from the World Health Organization (WHO) this month.
COVAXIN trial data for children aged 2-18 submitted to DCGI
Bharat Biotech has reportedly submitted trial data of its COVID-19 vaccine, COVAXIN, for children aged under 18 years to the Drugs and Comptroller General of India (DCGI).
Decision on EUL of COVAXIN in October, says WHO
A decision on Bharat Biotech's submission seeking emergency use listing (EUL) for its COVID-19 vaccine COVAXIN will be made in October, the World Health Organization has said.
India administers over 1 crore COVID-19 vaccines for 5th time
India administered more than one crore coronavirus vaccine doses on Monday, taking the cumulative number of administered doses in the country to above 86 crore, according to the Union Health Ministry.
COVAXIN for children: Bharat Biotech completes Phase 2/3 trials
Bharat Biotech has completed the Phase 2/3 trials of COVID-19 vaccine, COVAXIN for use in children under 18 years of age and is expected to submit the data by next week to the DCGI, Chairman, and Managing Director of Bharat Biotech International Ltd., Krishna Ella said.
Bharat Biotech awaits feedback from WHO for COVAXIN's EUL
Bharat Biotech on Friday said it has submitted all the data pertaining to its COVID-19 vaccine COVAXIN to the World Health Organization for EUL and is awaiting feedback from the global health watchdog.
WHO nod for COVAXIN expected by September-end: Report
NITI Aayog member Dr. VK Paul has said that India's indigenous COVID-19 vaccine COVAXIN's trial data looked promising, and the vaccine could soon get emergency-use approval from the World Health Organization (WHO) soon.
WHO seeks more data from Sputnik V makers for EUL
The World Health Organization has sought some more data from Russia's Gamaleya National Research Institute of Epidemiology and Microbiology, developer of COVID-19 vaccine Sputnik V for according Emergency Use Listing status to the jab.
Single COVAXIN dose might be enough for those previously infected
A single dose of Bharat Biotech's COVAXIN in previously COVID-19-infected individuals elicits a similar antibody response as obtained with two doses of the vaccine in those without a previous history of the disease, according to an ICMR study.
COVID-19 vaccine for children likely by September, says ICMR-NIV chief
India will likely have a COVID-19 vaccine for children by next month, Dr. Priya Abraham said in an interview.
India's drug regulator approves study on mixing Covishield, COVAXIN jabs
The Drugs Controller General of India (DCGI) has approved a proposal to conduct a study on the mixing of Covishield and COVAXIN COVID-19 vaccines.
Mixing of Covishield, COVAXIN vaccines gives positive results: ICMR study
A study conducted by the Indian Council of Medical Research (ICMR) has indicated that mixing and matching of COVID-19 vaccines Covishield and COVAXIN can yield better results.
Government expert panel recommends conducting trials on mixing Covishield, COVAXIN
The Subject Expert Committee (SEC) on COVID-19 of the Central Drugs Standard Control Organization (CDSCO) has given its go-ahead for conducting clinical trials involving the mixing and matching of Covishield and COVAXIN vaccine doses.
As vaccination pace remains slow, Centre may reduce private quota
The Centre may soon reduce the 25% quota of COVID-19 vaccine supply for private facilities for their failure to pick up the earmarked quota.
India to miss July vaccination target over low COVAXIN supply
India will miss its target to give out over 500 million (50 crore) coronavirus vaccine shots by the end of July, mainly because of low supplies of COVAXIN, its only indigenous jab so far.
Bharat Biotech ends its Brazil agreement. What went wrong?
Bharat Biotech on Friday announced the termination its agreement with two foreign firms for the supply of COVAXIN to Brazil.
COVID-19 vaccines for children likely by September, says AIIMS chief
India will likely have its first coronavirus vaccine for children by September, said Dr. Randeep Guleria, the chief of Delhi's All India Institute of Medical Sciences (AIIMS).
Bharat Biotech commits to supply 500mn COVAXIN doses to Centre
Bharat Biotech on Friday said it has committed to supply over 500 million doses of COVAXIN to the Centre under the countrywide immunization program.
Government to procure 66 crore doses of Covishield, COVAXIN
The Centre has placed an order to procure 66 crore doses of Covishield and COVAXIN to be supplied between August and December this year, at a revised price of Rs. 205 and Rs. 215 per dose, respectively, excluding taxes, official sources said.
Bharat Biotech enters contract manufacturing deal for COVAXIN drug substance
Hester Biosciences on Thursday said a memorandum of understanding (MoU) has been signed between Hyderabad-based vaccine maker Bharat Biotech and Gujarat COVID-19 Vaccine Consortium (GCVC) for contract manufacturing the drug substance for COVAXIN.
Zydus vaccine for 12-18-year-olds from September, says expert panel chief
Coronavirus vaccination for children with the Zydus Cadila vaccine will start by September, said Dr. NK Arora, the chief of National Expert Group on Vaccine Administration.
COVAXIN overall 77.8% effective in Phase-3 trial, says Bharat Biotech
COVAXIN, the coronavirus vaccine developed by India's Bharat Biotech, is overall 77.8 percent effective, the company said in a statement today, sharing the final analysis of its phase three trial data.
Seven EU nations, Switzerland approve India-made Covishield for 'Green Pass'
The European Union's (EU) Digital COVID Certificate framework to allow easier, restriction-free movement of vaccinated travelers within European countries—excluding India-made Covishield and COVAXIN vaccines—comes into force on Thursday.
Bharat Biotech denies wrongdoing in $324mn COVAXIN deal with Brazil
Hyderabad-based pharmaceutical company Bharat Biotech denied any wrongdoing on its part after Brazil suspended a $324 million contract for doses of its COVID-19 vaccine COVAXIN.
COVAXIN effectively neutralizes the Delta variant, top US body says
Through the coronavirus pandemic, we have seen many variants emerge and cause fatal outbreaks across the globe.
COVAXIN for children aged 2-18 by September, says AIIMS chief
India's first coronavirus vaccine for children could be ready by September, said Dr. Randeep Guleria, the chief of Delhi's All India Institute of Medical Sciences (AIIMS).
COVAXIN 77.8% effective; government panel reviews Phase III trial data
COVAXIN, the COVID-19 vaccine developed by Bharat Biotech, has been found 77.8% effective against the viral disease, Phase III trial data reportedly revealed.
Bharat Biotech submits COVAXIN phase-3 trial data, review meet today
Bharat Biotech has submitted the phase three clinical trial data for its coronavirus vaccine COVAXIN to the Drugs Controller General of India (DCGI).
Calf serum absent in COVAXIN, involved in development, government clarifies
COVAXIN, the indigenous COVID-19 vaccine produced by Bharat Biotech, does not contain calf serum, the Union Health Ministry clarified on Wednesday.
FDA rejects emergency-use approval of Bharat Biotech's COVAXIN
The United States' top drug regulator - the Food and Drug Administration - has rejected Bharat Biotech's application for an emergency use authorization for its COVID-19 vaccine COVAXIN.
After updating vaccine policy, Centre may renegotiate Covishield, COVAXIN prices
After India's COVID-19 vaccination policy was updated this week, the central government is likely to renegotiate prices for vaccines, a report suggested.
AIIMS-Delhi begins screening children for COVAXIN clinical trials from today
The All India Institute of Medical Sciences (AIIMS), Delhi will begin screening children from Monday to conduct clinical trials of the indigenously developed, Bharat Biotech's vaccine against COVID-19, COVAXIN.
Deck cleared for import of COVAXIN, Sputnik V into Brazil
Brazil has cleared the proposal to import Bharat Biotech's COVID-19 vaccine, COVAXIN, and Russia's COVID-19 vaccine Sputnik V into the South American country.
COVAXIN trials on children aged 2-18 begin at AIIMS-Patna
The All India Institute of Medical Sciences (AIIMS) in Patna has begun the clinical trials for COVAXIN on children, reports say.
Health Ministry thrashes reports about 'missing' COVAXIN doses
The Health Ministry has slammed news about unaccounted COVAXIN doses as "unfound media reports" adding that these reports are incorrect and not supported by full information on the matter.
4 crore COVAXIN doses missing? Mismatch in production, availability reported
Even as India is facing an acute vaccine shortage, a report indicates that there is a mismatch in the number of doses of COVAXIN produced and the number of doses administered.
Second drive-through vaccination camp inaugurated in Delhi
A two-day drive-through vaccination camp for people in the age group of 18-44 years was inaugurated by Delhi Deputy Chief Minister Manish Sisodia in Saket on Thursday, officials said.
1st dose Covishield, 2nd dose COVAXIN: Vaccination blunder in UP
In a grave oversight, a group of villagers in Uttar Pradesh received two shots of two different vaccines: COVAXIN and Covishield (both two-dose vaccines).
Need more information to give EUL to COVAXIN: WHO
The World Health Organization (WHO) has said that more information is required from Bharat Biotech, which is seeking emergency use listing (EUL) for its COVID-19 vaccine COVAXIN.
COVAXIN trials on children are expected to begin in June
Bharat Biotech, the pharmaceutical firm behind India's first indigenous COVID-19 vaccine COVAXIN, may begin trials on children in June and is expecting to receive the license in the third quarter of this year.
Karnataka targets vaccinating eligible population by 2021 end
The Karnataka government has set a goal to vaccinate all eligible people in the state by November end against coronavirus.
COVAXIN, Covishield effective, but produce fewer antibodies against B.1.617: Report
According to a series of early reports authored by scientists at the Indian Council of Medical Research (ICMR), COVAXIN and Covishield—vaccines deemed effective at generating an immune response against COVID-19—appear to generate only half as many antibodies against the B.1.617 variant.
COVAXIN approved for Phase 2/3 trials on 2-18-year-olds
India's apex drug regulator has granted permission for conducting the Phase II/III clinical trial of Bharat Biotech's COVAXIN in the age group of 2 to 18 years, the Union Health Ministry said on Thursday. The trial will be conducted on 525 healthy volunteers.
Government-owned BIBCOL to produce 2 crore COVAXIN doses every month
To accelerate the production of COVAXIN—the indigenous COVID-19 vaccine developed by Hyderabad-based Bharat Biotech—amid severe vaccine shortage in India, the Centre on Wednesday reportedly gave its nod for production of COVAXIN at government-owned Bharat Immunologicals & Biologicals Corporation Limited (BIBCOL) in Uttar Pradesh's Bulandshahr.
Bharat Biotech has refused additional COVAXIN doses to Delhi: Sisodia
Deputy Chief Minister Manish Sisodia on Wednesday said that Hyderabad-based Bharat Biotech has informed the Delhi government that it cannot provide "additional" doses of COVAXIN to the national capital.